{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:48:54Z","timestamp":1774529334972,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Collagenase clostridium histolyticum (CCH) is an injectable therapy targeting collagen present in penile plaques in Peyronie\u2019s disease (PD). Data comparing CCH to penile surgery are limited, and long-term therapeutic outcomes are unknown. This retrospective analysis used a US claims database (January 2014\u2013June 2017) to determine the percentage of men with subsequent penile surgery among those who initially received CCH (<jats:italic>n<\/jats:italic>\u2009=\u20091227) or surgery (index treatment; <jats:italic>n<\/jats:italic>\u2009=\u2009620) for PD. Eligible patients were aged \u226518 years with continuous enrollment \u22656 months before and \u226512 months after index treatment date. During 12 months of post-index treatment follow-up, fewer patients with PD initially treated with CCH (4.6% [56\/1227]) had subsequent penile surgery versus those initially treated with penile surgery (10.3% [64\/620]; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Mean\u2009\u00b1\u2009SD time to first subsequent surgery after initial PD treatment was longer in the CCH versus surgery cohort (7.7\u2009\u00b1\u20093.0 vs 1.7\u2009\u00b1\u20093.2 months). The likelihood of subsequent surgery varied by initial surgery type: 18.2% after plaque incision or excision with grafting; 11.6% after penile implant; and 8.2% after tunical plication. Patients with PD who received CCH first were less likely to undergo subsequent surgery compared with those who received surgery first within a 12-month post-treatment follow-up.<\/jats:p>","DOI":"10.1038\/s41443-021-00522-8","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T19:02:47Z","timestamp":1641841367000},"page":"147-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Penile surgery for patients with Peyronie\u2019s disease initially treated with collagenase clostridium histolyticum or surgery: a claims database analysis"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-733X","authenticated-orcid":false,"given":"Landon","family":"Trost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakkarin","family":"Burudpakdee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.sxmr.2019.06.004","volume":"8","author":"KL Sharma","year":"2020","unstructured":"Sharma KL, Alom M, Trost L. The etiology of Peyronie\u2019s disease: pathogenesis and genetic contributions. Sex Med Rev. 2020;8:314\u201323.","journal-title":"Sex Med Rev"},{"key":"522_CR2","first-page":"61","volume":"8","author":"KA Ostrowski","year":"2016","unstructured":"Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie\u2019s disease. Res Rep. Urol. 2016;8:61\u201370.","journal-title":"Res Rep. Urol"},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.esxm.2017.02.001","volume":"5","author":"I Goldstein","year":"2017","unstructured":"Goldstein I, Knoll LD, Lipshultz LI, Smith T, Kaufman GJ, McMahon CG. Changes in the effects of Peyronie\u2019s disease after treatment with collagenase Clostridium histolyticum: male patients and their female partners. Sex Med. 2017;5:e124\u2013e130.","journal-title":"Sex Med"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.21037\/tau.2018.04.06","volume":"7","author":"GF Wayne","year":"2018","unstructured":"Wayne GF, Cordon BH. Contemporary surgical and non-surgical management of Peyronie\u2019s disease. Transl Androl Urol. 2018;7:603\u201317.","journal-title":"Transl Androl Urol"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/bju.12565","volume":"113","author":"CC Carson","year":"2014","unstructured":"Carson CC, Levine LA. Outcomes of surgical treatment of Peyronie\u2019s disease. BJU Int. 2014;113:704\u201313.","journal-title":"BJU Int"},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.sxmr.2017.03.005","volume":"6","author":"AT Gabrielson","year":"2018","unstructured":"Gabrielson AT, Spitz JT, Hellstrom WJG. Collagenase clostridium histolyticum in the treatment of urologic disease: current and future impact. Sex Med Rev. 2018;6:143\u201356.","journal-title":"Sex Med Rev"},{"key":"522_CR7","unstructured":"Xiaflex\u00ae (collagenase clostridium histolyticum) for injection, for intralesional use [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; 2021."},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med. 2015;12:248\u201358.","journal-title":"J Sex Med"},{"key":"522_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/JU.0000000000000743","volume":"203","author":"I Goldstein","year":"2020","unstructured":"Goldstein I, Lipshultz LI, McLane M, Hu Y, Xiang Q, Liu G, et al. Long-term safety and curvature deformity characterization in patients previously treated with collagenase clostridium histolyticum for Peyronie\u2019s disease. J Urol. 2020;203:1191\u20137.","journal-title":"J Urol"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jsxm.2019.09.022","volume":"17","author":"S Sukumar","year":"2020","unstructured":"Sukumar S, Pijush DB, Brandes S. Impact of the advent of collagenase clostridium histolyticum on the surgical management of Peyronie\u2019s disease: a population-based analysis. J Sex Med. 2020;17:111\u20136.","journal-title":"J Sex Med"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.esxm.2021.100321","volume":"9","author":"L Trost","year":"2021","unstructured":"Trost L, Huang H, Han X, Burudpakdee C, Hu Y. Treatment patterns and healthcare outcomes with collagenase clostridium histolyticum vs surgery in Peyronie\u2019s disease: a retrospective claims database analysis. Sex Med. 2021;9:100321.","journal-title":"Sex Med"},{"key":"522_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/JU.0000000000000032","volume":"201","author":"WJG Hellstrom","year":"2019","unstructured":"Hellstrom WJG, Nguyen HMT, Alzweri L, Chung A, Virasoro R, Tapscott A, et al. Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie\u2019s disease: results of a multi-institutional analysis. J Urol. 2019;201:777\u201382.","journal-title":"J Urol"},{"key":"522_CR14","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","volume":"14","author":"HMT Nguyen","year":"2017","unstructured":"Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease. J Sex Med. 2017;14:1220\u20135.","journal-title":"J Sex Med"},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/jsm.12721","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Larsen SM. Surgical correction of persistent Peyronie\u2019s disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015;12:259\u201364.","journal-title":"J Sex Med"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urology.2017.08.037","volume":"110","author":"K DeLay","year":"2017","unstructured":"DeLay K, Diao L, Nguyen HMT, Zurawin J, Libby R, Yaf F, et al. Successful treatment of residual curvature in Peyronie disease in men previously treated with intralesional collagenase clostridium histolyticum. Urology. 2017;110:110\u20133.","journal-title":"Urology."},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jsxm.2020.02.002","volume":"17","author":"P Bajic","year":"2020","unstructured":"Bajic P, Wiggins AB, Ziegelmann MJ, Levine LA. Characteristics of men with Peyronie\u2019s disease and collagenase clostridium histolyticum treatment failure: predictors of surgical intervention and outcomes. J Sex Med. 2020;17:1005\u201311.","journal-title":"J Sex Med"},{"key":"522_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie\u2019s disease: AUA Guideline. J Urol. 2015;194:745\u201353.","journal-title":"J Urol"},{"key":"522_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/PPA.S113507","volume":"11","author":"PK Kuhlmann","year":"2017","unstructured":"Kuhlmann PK, DeLay KJ, Anaissie J, Hellstrom WJ, Yafi FA. Collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease: patient selection and perspectives. Patient Prefer Adherence. 2017;11:431\u201348.","journal-title":"Patient Prefer Adherence"},{"key":"522_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jsxm.2018.01.025","volume":"15","author":"E Chung","year":"2018","unstructured":"Chung E, Wang R, Ralph D, Levine L, Brock G. A worldwide survey on Peyronie\u2019s disease surgical practice patterns among surgeons. J Sex Med. 2018;15:568\u201375.","journal-title":"J Sex Med"},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/iju.14230","volume":"27","author":"MJ Ziegelmann","year":"2020","unstructured":"Ziegelmann MJ, Bajic P, Levine LA. Peyronie\u2019s disease: contemporary evaluation and management. Int J Urol. 2020;27:504\u201316.","journal-title":"Int J Urol"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1111\/j.1743-6109.2010.01971.x","volume":"7","author":"LA Levine","year":"2010","unstructured":"Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie\u2019s disease and drug-resistant erectile dysfunction: a single-center study. J Sex Med. 2010;7:3775\u201383.","journal-title":"J Sex Med"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00522-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T11:04:15Z","timestamp":1680001455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00522-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1038\/s41443-021-00522-8","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"9 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LT has no conflicts to disclose. HH, XH, and CB are former employees of IQVIA, a company that conducted this analysis with funding from Endo Pharmaceuticals Inc. YH is an employee of Endo Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}